Gemcitabine plus vinorelbine in nonsmall cell lung carcinoma patients age 70 years or older or patients who cannot receive cisplatin

Assessment of functional status, symptoms and comorbidity in elderly patients with advanced non-small-cell lung cancer (NSCLC) treated with gemcitabine and vinorelbine

“…In the scheme presented, both drugs were administered at optimal dose intensity once every 2 weeks and the myelotoxicity that usually occurs with the day 1 to 8 administration of a 21-day schedule was obviated. However response (22%) and survival (median of 29 weeks) were similar to that published before [30]. Notwithstanding, at present, such a long treatment would be questionable.…”

Combination chemotherapy of gemcitabine and vinorelbine for patients in stage IIIB–IV non-small cell lung cancer: a phase II study of the West Japan Thoracic Oncology Group (WJTOG) 9908

“…There are at least five phase II trials (results in full paper) in which gemcitabine and vinorelbine treatment has been given to chemo-naïve patients with advanced NSCLC. The observed response rate of 18% in our study was not better than that reported in other gemcitabine-vinorelbine regimens for advanced NSCLC, which have shown responses ranging from 25 to 72.5% [16][17][18][19][20]. It should be noted, however, that not only the dosage of gemcitabine and vinorelbine but also the timing of the drug administration was variable from study to study.…”

“…Feliu et al conducted a phase II study of a gemcitabine-vinorelbine regimen in NSCLC patients age 70 years or older or patients who cannot receive cisplatin [17]. Treatment comprised of vinorelbine, 25 mg/m 2 plus gemcitabine, 1000mg/m 2 , both on days 1, 8, and 15 every 28 days.…”

Gemcitabine and vinorelbine followed by docetaxel in patients with advanced non-small-cell lung cancer: a multi-institutional phase II trial of nonplatinum sequential triplet combination chemotherapy (JMTO LC00-02)

“…In particular, a GEM/VNR combination was very well tolerated with high activity (Feliu et al, 1999;Isokangas et al, 1999;Bajetta et al, 2000;Beretta et al, 2000;Gridelli et al, 2000). The Spanish Lung Cancer Group (Alberola et al, 2001) reported on a randomised comparison of a CDDP-based three-drug combination (CDDP/ GEM/VNR) vs non-CDDP sequential doublets (GEM/VNR followed by ifosphamide/VNR) vs CDDP/GEM (reference regimen).…”

“…Among the new drugs, GEM/VNR combination is noteworthy because of their demonstrated activity and particularly their good toxicity profile. This combination can also be used for elderly or unfit patients, because of its low toxicities (Feliu et al, 1999;Isokangas et al, 1999;Bajetta et al, 2000;Beretta et al, 2000;Gridelli et al, 2000). In addition, it has been shown that a single treatment of docetaxel (DOC) is active for NSCLC, especially as a second-line treatment (Fossella et al, 2000;Shephard et al, 2000).…”